MKK signaling and vascularization

Oncogene

Volumn 26, Issue 9, 2007, Pages 1290-1296

  Depeille, P E ^a   Ding, Y ^a   Bromberg White, J L ^a   Duesbery, N S ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Kinase

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; EMBRYO DEATH; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; LEOPARD SYNDROME; LETHALITY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; YOLK SAC;

ANIMALS; BLOOD VESSELS; HUMANS; MAP KINASE KINASE 1; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SYNDROME;

EID: 33847299406     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210198     Document Type: Review

References (78)

1. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S et al. (2000). Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6: 109-116.
2. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y et al. (2005). Germline mutations in HRAS protooncogene cause Costello syndrome. Nat Genet 37: 1038-1040.
3. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL et al. (2004). Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10: 849-857.
4. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J et al. (2005). Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25: 10454-10464.
5. Belanger LF, Roy S, Tremblay M, Brott B, Steff AM,MouradW et al. (2003). Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23: 4778-4787.
6. Bonnesen B, Orskov C, Rasmussen S, Holst PJ, Christensen JP, Eriksen KW et al. (2005). MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver. Blood 106: 3396-3404.
7. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. (2001). Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
8. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
9. Chang L, Karin M. (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
10. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B et al. (2001). MAP kinases. Chem Rev 101: 2449-2476.
11. Chi H, Sarkisian MR, Rakic P, Flavell RA. (2005). Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development. Proc Natl Acad Sci USA 102: 3846-3851.
12. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ et al. (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470-1478.
13. D'Angelo G, Struman I, Martial J, Weiner RI. (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92: 6374-6378.
14. Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
15. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. (1998). Defective T cell differentiation in the absence of Jnk1. Science 282: 2092-2095.
16. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH et al. (2001). Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 98: 4089-4094.
17. Duesbery NS,Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD et al. (1998). Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737.
18. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. (1998). Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140: 1255-1263.
19. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M et al. (2005). Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharm Exp Therap 313: 325-332.
20. Ergun S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S et al. (2001). Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 4: 193-206.
21. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. (2006). HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140: 8-16.
22. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS et al. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
23. Ferrara N, Henzel WJ. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
24. Fong GH, Rossant J, Gertsenstein M, Breitman ML. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
25. Fong GH, Zhang L, Bryce DM, Peng J. (1999). Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126: 3015-3025.
26. Fragale A, Tartaglia M, Wu J, Gelb BD. (2004). Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23: 267-277.
27. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA et al. (1998). SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA 95: 6881-6886.
28. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, Larouche L et al. (1999). Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9: 369-372.
29. Gripp KW. (2005). Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137: 72-77.
30. Hatano N, Mori Y, Oh-horaM, Kosugi A, Fujikawa T, Nakai N et al. (2003). Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 8: 847-856.
31. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. (2005). Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 65: 7699-7706.
32. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B et al. (2004). Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113: 1138-1148.
33. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D et al. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
34. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R et al. (2002). Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407.
35. Hood JD, Frausto R, KiossesWB, Schwartz MA, Cheresh DA. (2003). Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 162: 933-943.
36. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S et al. (2001). MEK kinase activity is not necessary for Raf-1 function. EMBO J 20: 1940-1951.
37. Johnson GL, Lapadat R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
38. Keren B, Hadchouel A, Saba S, Sznajer Y, Bonneau D, Leheup B et al. (2004). PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41: e117.
39. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
40. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. (2005). PTPN11 (SHP2) mutations in leopard syndrome have dominant negative, not activating, effects. J Biol Chem 281: 6785-6792.
41. Kowanetz M, Ferrara N. (2006). Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022.
42. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ et al. (1999). Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 18: 1845-1857.
43. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
44. MacKeigan JP, Collins TS, Ting JP. (2000). MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275: 38953-38956.
45. Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L. (2002). p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 156: 149-160.
46. Merks JH, Caron HN, Hennekam RC. (2005). High incidence of malformation syndromes in a series of 1073 children with cancer. Am J Med Genet A 134: 132-143.
47. Mikula M, Schreiber M, Husak Z, Kucerova L, Ruth J, Wieser R et al. (2001). Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 20: 1952-1962.
48. Milanini J, Vinals F, Pouyssegur J, Pages G. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273: 18165-18172.
49. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, Gopal S et al. (2000). Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 97: 10454-10459.
50. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A et al. (2006). Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38: 294-296.
51. Nishina H, Vaz C, Billia P, Nghiem M, Sasaki T, De la Pompa JL et al. (1999). Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 126: 505-516.
52. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. (2000). Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275: 26484-26491.
53. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F et al. (1999). Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286: 1374-1377.
54. Pedram A, Razandi M, Levin ER. (1998). Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722-26728.
55. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. (2002). Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99: 9248-9253.
56. Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV et al. (1986). New multiple congenital anomalies/mental retardation syndrome with cardiofacio-cutaneous involvement - the CFC syndrome. Am J Med Genet 25: 413-427.
57. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Santa Cruz M et al. (2006). Germline mutations in genes within the MAPK pathway cause cardio-faciocutaneous syndrome. Science 311: 1287-1290.
58. Rousseau S, Houle F, Landry J, Huot J. (1997). p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169-2177.
59. Roux PP, Blenis J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
60. Ruegg C, Mariotti A. (2003). Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 60: 1135-1157.
61. Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, Labrecque N et al. (2003). An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4: 964-968.
62. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
63. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML et al. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
64. Shin EY, Kim SY, Kim EG. (2001). c-Jun N-terminal kinase is involved in motility of endothelial cell. Expt Mol Med 33: 276-283.
65. Sohn SJ, Sarvis BK, Cado D, Winoto A. (2002). ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277: 43344-43351.
66. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. (2000). Genes expressed in human tumor endothelium. Science 289: 1197-1202.
67. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. (2000). Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 102: 221-231.
68. Tanaka N, Kamanaka M, Enslen H, Dong C, Wysk M, Davis RJ et al. (2002). Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep 3: 785-791.
69. Tartaglia M, Gelb BD. (2005). Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6: 45-68.
70. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. (2000). Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 352(Part 3): 739-745.
71. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG et al. (2005). Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 25: 336-345.
72. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
73. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR et al. (1997). Endothelial apoptosis in Braf-deficient mice. Nat Genet 16: 293-297.
74. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
75. Yan L, Carr J, Ashby PR, Murry-Tait V, Thompson C, Arthur JS. (2003). Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol 3: 11.
76. Yang D, Tournier C, Wysk M, Lu HT, Xu J, Davis RJ et al. (1997). Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 94: 3004-3009.
77. Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M et al. (1998). Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9: 575-585.
78. Yang J, Boerm M, McCarty M, Bucana C, Fidler IJ, Zhuang Y et al. (2000). Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 24: 309-313.